^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABL501

    i
    Other names: ABL501, ABL 501, ABL-501
    Associations

    News

    Trials
    Company:
    ABL Bio, Handok
    Drug class:
    PD-L1 inhibitor, LAG-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=24, Completed, ABL Bio, Inc. | Recruiting --> Completed | N=36 --> 24 | Trial completion date: Dec 2024 --> May 2024
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    ABL501
    9ms
    Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=36, Recruiting, ABL Bio, Inc. | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    ABL501
    over2years
    LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation. (PubMed, Mol Ther)
    The immune profiling analysis of peripheral blood reveals an increased abundance of LAG-3PD-1 memory CD4T cell subset in relapsed cholangiocarcinoma patients after gemcitabine plus cisplatin therapy, which are more responsive to ABL501. This study supports the clinical evaluation of ABL501 as a novel cancer immunotherapeutic, and a first-in-human trial has started (NCT05101109).
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    cisplatin • gemcitabine • ABL501
    over3years
    [VIRTUAL] ABL501, PD-L1 x LAG-3, a bispecific antibody promotes enhanced human T cell activation through targeting simultaneously two immune checkpoint inhibitors, LAG-3 and PD-L1 (AACR 2021)
    Together with safety profile in the toxicology study, the preclinical studies support that ABL501 effectively suppressed tumor growth through activation of immune cells by releasing immune suppressive environments. This alternative therapeutic strategy may have a potential to overcome limitations of the current immune-oncology therapy for further clinical evaluation.
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3)
    |
    LAG3 expression
    |
    ABL501